At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 450 enrolled
Drug / intervention
Paclitaxel-eluting stent (Taxus) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)
In Brief
A Phase 4 clinical trial evaluating Paclitaxel-eluting stent (Taxus) and Rapamycin-eluting stent for Coronary Disease. Completed, enrolled 450 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the efficacy of nonpolymer-based rapamycin-eluting stent compared to standard polymer-based paclitaxel-eluting stent to reduce reblockage of coronary arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesGermany
CollaboratorsBayerische Forschungsstiftung Muenchen
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2004
Study CompletionJun 2005
First PostedSep 2005
TodayJul 2026
First PostedSep 1, 2005
Enrollment StartMar 1, 2004
Study CompletionJun 1, 2005
TodayJul 1, 2026
Posted 20.8 years ago
Interventions
Paclitaxel-eluting stent (Taxus)device
patients has been implanted the Paclitaxel-eluting stent.
Rapamycin-eluting stentdevice
patients has been implanted the Rapamycin-eluting stent.